Role of sputum biomarkers in the management of asthma

Current Opinion in Pulmonary Medicine

Volumn 23, Issue 1, 2017, Pages 34-40

  Seys, Sven F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Eosinophil; Inflammatory phenotype; Neutrophil; Precision medicine; Sputum

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE;

ASTHMA; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; EOSINOPHIL; HUMAN; LOWER RESPIRATORY TRACT; MAST CELL; NEUTROPHIL; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM; SPUTUM ANALYSIS; TREATMENT RESPONSE; DISEASE EXACERBATION; IMMUNOLOGY; METABOLISM;

ADRENAL CORTEX HORMONES; ASTHMA; BIOMARKERS; CYTOKINES; DISEASE PROGRESSION; HUMANS; SPUTUM;

EID: 85007380984     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000345     Document Type: Review

References (92)

1. Anderson GP. Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-1119.
2. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
3. Alexis NE. Biomarker sampling of the airways in asthma. Curr Opin Pulm Med 2014; 20: 46-52.
4. Pavord ID, Sterk PJ, Hargreave FE, et al. Clinical applications of assessment of airway inflammation using induced sputum. Eur Respir J 2002; 20: 40s-43s.
5. Chanez P, Holz O, Ind PW, et al. Sputum induction. Eur Respir J 2002; 20 (Supplement 37): 3s-8s.
6. Spanevello A, Migliori GB, Sharara A, et al. Induced sputum to assess airway inflammation: A study of reproducibility. Clin Exp Allergy J 1997; 27: 1138-1144.
7. Kupczyk M, Dahlén B, Sterk PJ, et al. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 2014; 69: 1198-1204.
8. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-tomoderate asthma is persistently non-eosinophilic. Am J Respir Crit Care Med 2012; 185: 612-619.
9. Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS 2010; 5: 463-466.
10. Parulekar AD, Diamant Z, Hanania NA. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med 2016; 22: 59-68.
11. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2015; 16: 45-56.
12. Fahy JV. Type 2 inflammation in asthma -present in most, absent in many. Nat Rev Immunol 2015; 15: 57-65.
13. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-1008.
14. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: Identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-879.
15. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: Assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
16. Hinks T, Zhou X, Staples K, et al. Multidimensional endotypes of asthma: Topological data analysis of cross-sectional clinical, pathological, and immunological data. Lancet 2015; 385 (Suppl 1): S42.
17. Hinks TSC, Brown T, Lau LCK, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol 2016; 138: 61-75.
18. Kuo C-HS, Pavlidis S, Loza M, et al. A transcriptome-driven analysis of epithelial brushings and bronchial biopsies to define asthma phenotypes in U-BIOPRED. Am J Respir Crit Care Med 2016. [Epub ahead of print]. doi: 10.164/rccm.201512-2452OC.
19. Agache IO. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 2013; 13: 249-256.
20. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis -PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016; 137: 1347-1358.
21. Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13: 11.
22. Amelink M, de Groot JC, de Nijs SB, et al. Severe adult-onset asthma: A distinct phenotype. J Allergy Clin Immunol 2013; 132: 336-341.
23. de Groot JC, Amelink M, de Nijs SB, et al. Risk factors for frequent severe exacerbations in late-onset eosinophilic asthma. Am J Respir Crit Care Med 2015; 192: 899-902.
24. Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004; 114: 1106-1109.
25. Truyen E, Coteur L, Dilissen E, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax 2006; 61: 202-208.
26. Beale J, Jayaraman A, Jackson DJ, et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med 2014; 6: 256ra134.
27. Agache I, Sugita K,Morita H, et al. The complex type 2 endotype in allergy and asthma: From laboratory to bedside. Curr Allergy Asthma Rep 2015; 15: 29.
28. Westerhof GA, Korevaar DA, Amelink M, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 2015; 46: 688-696.
29. Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115-120.
30. Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: A systematic review and meta-analysis. Lancet Respir Med 2015; 3: 290-300.
31. Schleich FN, Chevremont A, Paulus V, et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44: 97-108.
32. Demarche S, Schleich F, Henket M, et al. Detailed analysis of sputum and systemic inflammation in asthma phenotypes: Are paucigranulocytic asthmatics really non-inflammatory? BMC Pulm Med 2016; 16: 46.
33. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-654.
34. Simpson JL, Yang IA, Upham JW, et al. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med 2016; 16: 67.
35. Nair P, Ochkur SI, Protheroe C, et al. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy 2013; 68: 1177-1184.
36. Kulkarni NS, Hollins F, Sutcliffe A, et al. Eosinophil protein in airway macrophages: A novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol 2010; 126: 61-69.
37. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133: 1557-1563.
38. Brooks CR, Gibson PG, Douwes J, et al. Relationship between airway neutrophilia and ageing in asthmatics and non-asthmatics. Respirology 2013; 18: 857-865.
39. Wood LG, Baines KJ, Fu J, et al. The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest 2012; 142: 86-93.
40. Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol 2014; 133: 997-1007.
41. Konradsen JR, Nordlund B, Levänen B, et al. The cytokine interleukin-26 as a biomarker in pediatric asthma. Respir Res 2016; 17: 32.
42. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162: 2347-2352.
43. Bullens DM, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of asthmatic patients: Linking T cell driven inflammation and granulocytic influx? Respir Res 2006; 7: 135.
44. Chesné J, Braza F, Mahay G, et al. IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med 2014; 190: 1094-1101.
45. Wallace J, D'silva L, Brannan J, et al. Association between proximity to major roads and sputum cell counts. Can Respir J 2011; 18: 13-18.
46. McCreanor J, Cullinan P, Nieuwenhuijsen MJ, et al. Respiratory effects of exposure to diesel traffic in persons with asthma. N Engl J Med 2007; 357: 2348-2358.
47. Nwokoro C, Ewin C, Harrison C, et al. Cycling to work in London and inhaled dose of black carbon. Eur Respir J 2012; 40: 1091-1097.
48. Bai Y, Brugha RE, Jacobs L, et al. Carbon loading in airway macrophages as a biomarker for individual exposure to particulate matter air pollution -A critical review. Environ Int 2015; 74: 32-41.
49. St-Laurent J, Bergeron C, Pagé N, et al. Influence of smoking on airway inflammation and remodelling in asthma. Clin Exp Allergy 2008; 38: 1582-1589.
50. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57: 226-230.
51. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175: 783-790.
52. Seys SF, Daenen M, Dilissen E, et al. Effects of high altitude and cold air exposure on airway inflammation in patients with asthma. Thorax 2013; 68: 906-913.
53. Bougault V, Turmel J, St-Laurent J, et al. Asthma, airway inflammation and epithelial damage in swimmers and cold-air athletes. Eur Respir J 2009; 33: 740-746.
54. Seys SF, Hox V, Van Gerven L, et al. Damage-associated molecular pattern and innate cytokine release in the airways of competitive swimmers. Allergy 2015; 70: 187-194.
55. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-224.
56. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J RespirCrit Care Med 2009; 181: 315-323.
57. Desai D, Newby C, Symon FA, et al. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med 2013; 188: 657-663.
58. Marijsse GS, Seys SF, Schelpe A-S, et al. Obese individuals with asthma preferentially have a high IL-5/IL-17A/IL-25 sputum inflammatory pattern. Am J Respir Crit Care Med 2014; 189: 1284-1285.
59. Scott HA, Gibson PG, Garg ML, et al. Sex hormones and systemic inflammation aremodulators of the obese-asthma phenotype. Allergy 2016; 71: 1037-1047.
60. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109: 410-418.
61. CowanDC, TaylorDR, Peterson LE, et al. Biomarker-based asthmaphenotypes of corticosteroid response. J Allergy Clin Immunol 2015; 135: 877-883.
62. Kupczyk M, Haque S, Middelveld RJM, et al. Phenotypic predictors of response to oral glucocorticosteroids in severe asthma. Respir Med 2013; 107: 1521-1530.
63. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
64. Cheng D, Xue Z, Yi L, et al. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med 2014; 190: 639-648.
65. Wang G, Baines KJ, Fu JJ, et al. Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma. Eur Respir J 2016; 47: 1123-1133.
66. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115: 720-727.
67. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062-1071.
68. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-2148.
69. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
70. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
71. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
72. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371: 1189-1197.
73. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198-1207.
74. Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: A secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 2016; 4: 549-556.
75. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 41: 330-338.
76. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
77. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: Pooled data from two randomised placebo-controlled studies. Thorax 2015; 70: 748-756.
78. Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3: 692-701.
79. Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68: 322-329.
80. Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: A randomized, placebocontrolled clinical trial. Clin Exp Allergy 2012; 42: 1097-1103.
81. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188: 1294-1302.
82. Walsh CJ, Zaihra T, Benedetti A, et al. Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils. Clin Exp Allergy 2016; 46: 1291-1302.
83. Newby C, Agbetile J, Hargadon B, et al. Lung function decline and variable airway inflammatory pattern: Longitudinal analysis of severe asthma. J Allergy Clin Immunol 2014; 134: 287-294.
84. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and metaanalysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
85. Jayaram L. Determining asthma treatment by monitoring sputum cell counts: Effect on exacerbations. Eur Respir J 2006; 27: 483-494.
86. Seys SF, Grabowski M, Adriaensen W, et al. Sputum cytokine mapping reveals an ''IL-5, IL-17A, IL-25-high'' pattern associated with poorly controlled asthma. Clin Exp Allergy 2013; 43: 1009-1017.
87. Esnault S, Kelly EA, Sorkness RL, et al. Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients. J Allergy Clin Immunol 2016; 137: 767-773.
88. Tsilogianni Z, Hillas G, Bakakos P, et al. Sputum interleukin-13 as a biomarker for the evaluation of asthma control. Clin Exp Allergy 2016; 46: 923-931.
89. Zuiker RGJA, Tribouley C, Diamant Z, et al. Sputum RNA signature in allergic asthmatics following allergen bronchoprovocation test. Eur Clin Respir J 2016; 3: 31324.
90. Castro M, Marthur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
91. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial. Lancet 2002; 30: 1715-1721.
92. Chlumsky J, Striz I, Terl M, et al. Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34: 129-139.